AU2021229482A1 - A pharmaceutical composition and method of treatment using Serratiopeptidase, Mannose or its derivative, and optionally antinfection agents - Google Patents

A pharmaceutical composition and method of treatment using Serratiopeptidase, Mannose or its derivative, and optionally antinfection agents Download PDF

Info

Publication number
AU2021229482A1
AU2021229482A1 AU2021229482A AU2021229482A AU2021229482A1 AU 2021229482 A1 AU2021229482 A1 AU 2021229482A1 AU 2021229482 A AU2021229482 A AU 2021229482A AU 2021229482 A AU2021229482 A AU 2021229482A AU 2021229482 A1 AU2021229482 A1 AU 2021229482A1
Authority
AU
Australia
Prior art keywords
mannose
serratiopeptidase
pharmaceutical composition
therapeutically effective
infectious disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021229482A
Other languages
English (en)
Inventor
Nimesh Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2021229482A1 publication Critical patent/AU2021229482A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/2404—Serralysin (3.4.24.40)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021229482A 2020-03-02 2021-03-02 A pharmaceutical composition and method of treatment using Serratiopeptidase, Mannose or its derivative, and optionally antinfection agents Pending AU2021229482A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984135P 2020-03-02 2020-03-02
US62/984,135 2020-03-02
PCT/US2021/020411 WO2021178371A1 (en) 2020-03-02 2021-03-02 A pharmaceutical composition and method of treatment using serratiopeptidase, mannose or its derivative, and optionally antinfection agents

Publications (1)

Publication Number Publication Date
AU2021229482A1 true AU2021229482A1 (en) 2022-07-28

Family

ID=77463237

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021229482A Pending AU2021229482A1 (en) 2020-03-02 2021-03-02 A pharmaceutical composition and method of treatment using Serratiopeptidase, Mannose or its derivative, and optionally antinfection agents

Country Status (9)

Country Link
US (1) US20210268075A1 (https=)
EP (1) EP4114407A4 (https=)
JP (1) JP7758906B2 (https=)
CN (1) CN115361953A (https=)
AU (1) AU2021229482A1 (https=)
BR (1) BR112022016132A2 (https=)
CA (1) CA3164767A1 (https=)
WO (1) WO2021178371A1 (https=)
ZA (1) ZA202209623B (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007099639A (ja) * 2005-09-30 2007-04-19 Towa Chem Ind Co Ltd 除菌洗浄剤
WO2008035370A2 (en) * 2006-07-10 2008-03-27 Advanced Enzyme Technologies Limited Compositions for prevention and treatment of mastitis and metritis
EP2690105A1 (en) * 2012-07-24 2014-01-29 Centre National De La Recherche Scientifique Mannose derivatives, a process for preparing the same and their uses as a drug
ITMI20130793A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
CN105682665A (zh) * 2013-05-30 2016-06-15 华盛顿大学 用于治疗细菌性感染的化合物和方法
US20190000908A1 (en) * 2017-06-29 2019-01-03 Hms Laboratories Ltd. Compositions and methods for treating and/or preventing a urinary tract infection
US11707065B2 (en) * 2017-07-18 2023-07-25 Mc (Us) 3 Llc Method for biofilm dispersal
CN116115768B (zh) * 2022-12-01 2025-03-18 西南民族大学 一种抗菌剂及其制备方法和应用

Also Published As

Publication number Publication date
US20210268075A1 (en) 2021-09-02
BR112022016132A2 (pt) 2023-01-10
ZA202209623B (en) 2023-12-20
EP4114407A1 (en) 2023-01-11
WO2021178371A1 (en) 2021-09-10
CN115361953A (zh) 2022-11-18
CA3164767A1 (en) 2021-09-10
JP2023515880A (ja) 2023-04-14
JP7758906B2 (ja) 2025-10-23
EP4114407A4 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
US11839208B2 (en) Cannabidiol compositions and uses thereof
JP5469511B2 (ja) 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
Seyman et al. Pseudomonas aeruginosa septic arthritis of knee after intra-articular ozone injection
WO2021068614A1 (zh) 和厚朴酚及厚朴酚在制备mcr-1酶抑制剂中的应用
CN116139143B (zh) 天然药物在制备抗革兰氏阳性菌药物中的应用
EP2167081B1 (en) Bactericidal anti-mrsa active pharmaceutical composition containing carbapenems
CN107714678B (zh) 紫檀芪在制备mcr-1酶抑制剂中的应用
JP7758906B2 (ja) セラチオペプチダーゼ、マンノースまたはその誘導体および任意に抗感染薬剤を使用する医薬組成物ならびに処置の方法
Girard et al. The comparative activity of azithromycin, macrolides and amoxycillin against streptococci in experimental infections
CN110772518A (zh) 血根碱在抑制路邓葡萄球菌生长中的应用
CN105853449B (zh) 一种注射用硫酸阿米卡星的抗菌组合药物
CN110876749B (zh) 白屈菜红碱在抑制多重耐药粘质沙雷菌生长中的应用
Brook Microbiology and management of post-surgical wounds infection in children
WO2022189364A1 (en) Associations of fosfomycin and colistin for use against biofilm-associated bacterial infections
Plaut et al. Staphylococcal bacteremia in a germ-free unit
Sheagren Staphylococci
Speller et al. Experience with amikacin and colistin in an outbreak of infection by resistant Klebsiella aerogenes
CN105998029A (zh) 一种注射用盐酸左氧氟沙星的抗菌组合药物
CN116687891B (zh) 苯基氯化硒的应用
RU2794585C2 (ru) Способ лечения и профилактики рецидивов нозокомиальной пневмонии
CN102125562A (zh) 一种治疗超级细菌的注射用药物组合物
Sagar et al. Era of Antibiotic Discovery
HK40065985A (zh) 大麻二酚组合物
CN114159455A (zh) 利巴韦林在制备抗鲍曼不动杆菌药物中的应用
Lubitz Resolution of lung abscess due to Pseudomonas aeruginosa with oral ciprofloxacin: case report